Relacorilant

Domenica Lorusso discusses findings from a phase 2 trial evaluating relacorilant plus nab-paclitaxel in recurrent, platinum-resistant ovarian cancer, showing significant improvements in PFS, overall survival, response rate, and DOR. The results led to the ongoing phase 3 ROSELLA trial comparing nab-paclitaxel alone with the combination in eligible patients.

Relacorilant, a selective glucocorticoid receptor modulator, enhances nab-paclitaxel efficacy in platinum-resistant ovarian cancer. Phase 2 trial results showed improved progression-free survival and duration of response with the combination. The ongoing phase 3 ROSELLA trial aims to confirm these benefits in a larger patient population.

Glucocorticoid-induced hypercoagulopathy in endogenous Cushing syndrome (CS) increases thromboembolic risk, with CS patients having an 18-fold higher risk of venous thromboembolism (VTE) compared to the general population. VTE risk is highest postoperatively, with up to 5.6% incidence. Hypercoagulopathy persists post-surgery and improves within 6 months. Relacorilant, a selective glucocorticoid receptor modulator, showed improvements in coagulation markers without undesirable effects, suggesting potential benefits for CS patients, particularly those at high VTE risk.

Biomarkers are crucial in healthcare and drug development, aiding in disease prediction, monitoring, and treatment response assessment. Despite challenges in discovery and validation, they enhance clinical trial precision and cost-effectiveness. Omics technologies and collaborative efforts are key to overcoming these challenges, with companies like Mission Bio and Precision for Medicine leading advancements.